Raynaud’s phenomenon and positive antinuclear antibodies as first manifestation of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes): a case report

Fabio Torres-Saavedra1,2* and Lina León-Sierra3

Abstract

Background: POEMS syndrome is a rare paraneoplastic syndrome caused by plasma cell disorder almost always lambda restricted. Secondary Raynaud's phenomenon is an overlooked skin manifestation of the disease even though it is present in twenty percent of patients. On POEMS syndrome have not been described positive antinuclear antibodies (ANA) and this could lead to a misdiagnosis of autoimmune disease, mainly systemic sclerosis.

Case presentation: A 47-year-old man presented with color changes on fingertips consistent with biphasic Raynaud's phenomenon; an antinuclear antibody test was positive (at 1:320 titers in a speckled pattern) with normal nailfold capillaroscopy. Clinical features of systemic sclerosis were absent. Twenty-four months later, the patient presented symmetric sensorimotor demyelinating polyneuropathy, and he was diagnosed with Guillain–Barre syndrome; treatment with intravenous gammaglobulin had an incomplete response. Raynaud's phenomenon persisted associated with acrocyanosis, white nails, and positive ANA (1:1280 in a nucleolar pattern). POEMS syndrome was suspected, and serum protein electrophoresis (SPEP) was done. The SPEP revealed polyclonal gammopathy, and serum immunofixation showed monoclonal (M)-protein (IgG lambda). Serum vascular endothelial growth factor concentration showed increased levels. The patient was diagnosed with POEMS syndrome, and treatment with lenalidomide and dexamethasone improved the Raynaud's phenomenon, acrocyanosis, and white nails, but the neurological response was partial.

Conclusions: POEMS syndrome may mimic clinical manifestations of systemic sclerosis v.g. Raynaud's phenomenon, skin thickening, telangiectasia, and positive ANA. Raynaud's phenomenon may precede other clinical manifestations of POEMS syndrome by several months. It is necessary to have a high index of suspicion for the diagnosis, especially in patients with peripheral polyneuropathy and monoclonal paraprotein. The significance of positive ANA in this condition is unknown and deserves further investigation.

Keywords: Raynaud disease, POEMS syndrome, Paraneoplastic polyneuropathy, Autoimmune disease, Case report

*Correspondence: fabio.torressav@gmail.com
1 Division of Rheumatology, GRUA Investigation Group, Universidad de Antioquia, 050010 Medellín, Colombia
Full list of author information is available at the end of the article

Background

POEMS syndrome is a rare disease described for the first time in 1938. In 1980, the acronym "POEMS" was suggested to describe the clinical features of this syndrome. It is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.
disease (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes).

In recent years POEMS syndrome has been widely recognized. However, prevalence studies are scarce. A nationwide epidemiologic survey in Japan estimated a prevalence of 0.3 per 100,000 and is considered less in western countries [1].

This disorder is defined by the presence of peripheral neuropathy and a monoclonal plasma cell disorder (IgA/IgG lambda restricted) [2]. Other manifestations are Castleman’s disease, sclerotic bone lesions, organomegaly, extravascular volume overload, increased cerebrospinal fluid protein, endocrinopathy, skin changes, papilledema, thrombocytosis, polycythemia, thromboembolic disease, and elevated VEGF levels.

The cause of the syndrome is unknown, although increased levels of proinflammatory and proangiogenic cytokines, including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and VEGF have been reported [3].

The prevalence of cutaneous manifestations in POEMS syndrome is approximately 68–90 percent [4, 5]. Skin changes in POEMS syndrome are overlooked, in a retrospective study from Mayo Clinic, the mean number of skin findings per patient was 2.9 (median 3; range 0–7) (Table 1) [5]. Raynaud’s phenomenon frequently encompasses other manifestations of POEMS syndrome and is an important feature of the disease. A significant association exists between vascular skin changes and abnormal pulmonary function tests [5].

For that reason, secondary Raynaud’s phenomenon is a relevant clue for POEMS syndrome diagnosis and is necessary to establish a rational approach with other diseases that present Raynaud’s phenomenon, mainly autoimmune diseases. We report a case of POEMS syndrome whose first manifestations were Raynaud’s phenomenon and positive antinuclear antibodies.

Case presentation
A 47-year-old man presented to the clinic reporting color changes on fingertips, initially pale fingers, followed by blue discoloration and numbness. He denied photosensitivity, oral ulcers, skin changes, cough, dyspnea, gastrointestinal symptoms, or urinary changes. Medical history was remarkable for recurrent superficial venous thrombosis of the left leg treated with rivaroxaban.

Physical examination revealed pale fingers with hypertrichosis without puffy fingers, sclerodactyly, telangiectasia, digital ulcers, or calcinosis cutis. No hepatosplenomegaly or lymphadenopathy was present. Initial laboratory studies showed elevated platelets (479 × 10^9/L, reference value 150–450) with normal hemoglobin concentration (15.3 g/dL, reference value 11.5–15.5), hematocrit levels (44%, reference value 41–50), acute phase reactants (ESR and CRP), thyroid-stimulating hormone (TSH), clotting profile (PT and TPT), creatinine, and B12 vitamin levels. ANA were positive at 1:320 titers in a speckled pattern. Tests for extractable nuclear antigen (ENA), anti-dsDNA titers, complement, antiphospholipid antibodies, cryoglobulins, antineutrophil cytoplasmic antibody (ANCA) by direct immunofluorescence, and nailfold capillaroscopy were unremarkable. Therefore, a diagnosis of secondary Raynaud’s phenomenon was made, treatment with acetylsalicylic acid was initiated.

Twenty-four months later, the patient had paraparesis due to symmetric sensorimotor demyelinating polyneuropathy, and he was diagnosed with Guillain–Barre syndrome. Intravenous gammaglobulin (IVIg) was initiated at 0.4 g/kg/ day for five days, with an incomplete response. Raynaud’s phenomenon persisted, associated with acrocyanosis, hypertrichosis, and white nails (Fig. 1a, b). Additional laboratory test results were received, and ANA was positive but with a different pattern (1:1280 in a nucleolar pattern); serum protein electrophoresis revealed a polyclonal gammopathy with a monoclonal (M)-protein on immunofixation (IgG lambda), and increased concentrations of VEGF (827 pg/mL, reference value 31–86 pg/mL). 24-h urine protein measurement was 130 mg of protein per day (reference value: less than 150 mg per day), and a radiographic bone survey did not reveal sclerotic bone lesions. Another nailfold capillaroscopy was unremarkable, and tests for ENA and antiphospholipid antibodies were normal.

The Rheumatology staff proposed amyloidosis as a differential diagnosis due to the identification of monoclonal gammapathy and peripheral neuropathy. However, the patient did not have autonomic neuropathy, which

Table 1 Prevalence of cutaneous manifestations in POEMS syndrome [4]

| Feature                  | Patient (%) |
|--------------------------|-------------|
| Hyperpigmentation        | 50 (47)     |
| Hemangioma               | 50 (47)     |
| Hypertrichosis           | 41 (38)     |
| Acrocyanosis             | 36 (34)     |
| White nails              | 32 (30)     |
| Sclerodermoid changes    | 28 (26)     |
| Raynaud’s Phenomenon     | 21 (20)     |
| Hyperemia/erythema       | 21 (20)     |
| Flushing                 | 17 (16)     |
| Rubor                    | 12 (11)     |
| Clubbing                 | 6 (6)       |
may be present in 15% of patients with AL amyloidosis. Entrapment neuropathies such as carpal tunnel syndrome are frequent, but this manifestation was absent in our patient. Skin manifestations in amyloidosis are periorbital purpura, waxy thickening, macroglossia, and subcutaneous nodules. Nevertheless, a few cases with Raynaud’s syndrome have been described [6].

Another differential diagnosis proposed was type I cryoglobulinemia which frequently can occur with Raynaud’s phenomenon and peripheral neuropathy. In our case, the patient had demyelinating polyneuropathy compared to cryoglobulinemia, which occurs with sensory-motor axonal polyneuropathy. Other peripheral nervous system manifestations of cryoglobulinemia include small-fiber polyneuropathy and mononeuritis multiplex [7].

Based on the initial presence of superficial venous thrombosis, thrombocytosis, Raynaud’s phenomenon, hypertrichosis, white nails, acrocyanosis, and with the onset of demyelinating peripheral neuropathy, monoclonal gammopathy, and elevated levels of VEGF, the patient was diagnosed with POEMS syndrome by the Hematology group.

The bone marrow showed megakaryocytic hyperplasia and increased atypical plasma cells by 5 percent. Treatment with lenalidomide and dexamethasone was initiated, with the improvement of Raynaud’s phenomenon, acrocyanosis, and white nails. The patient showed neurologic partial response after 6 months and required a walker brace and physical therapy for mobility (Fig. 2). Autologous hematopoietic cell transplantation was proposed, pending authorization by the patient.

**Discussion and conclusions**

POEMS syndrome presents with skin changes in 68–90 percent of patients, but Raynaud’s phenomenon is frequently overlooked [2]. It is present in twenty percent of patients and could be the first manifestation.
of this disease. The search for other skin lesions such as hemangiomas, hyperpigmentation, hypertrichosis, white nails, acrocyanosis, sclerodermoid changes, and hyperemia is important in the differential diagnosis of Raynaud’s phenomenon secondary to POEMS syndrome [3]. In our patient, the initial manifestations in the skin (minor criteria for the diagnosis) were followed by the presence of mandatory criteria (polyneuropathy, monoclonal gammapathy, and skin changes; ANA: Antinuclear antibodies; SPEP: Serum protein electrophoresis; VEGF: Vascular endothelial growth factor; SSC: Systemic sclerosis; IL-1β: Interleukin-1 beta; TNF-α: Tumor necrosis factor alpha; IL-6: Interleukin-6; TSH: Thyroid-stimulating hormone; ENA: Extractable nuclear antigen; ANCA: Antineutrophil cytoplasmic antibody; IVIg: Intravenous gammaglobulin; AMA: Antimitochondrial antibody.

Acknowledgements
None.

Authors’ contributions
We were all involved in the concept, design, and writing of the manuscript. FT was involved directly in the caring of the patient. LL wrote the first draft and reviewed the manuscript. FT edited the images and reviewed the manuscript. All authors read and approved the final manuscript.

Funding
The authors don’t receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
We obtained written consent from the patient for publication of this clinical case together with any accompanying images.

Competing interests
The authors declare no competing interests.

Author details
1 Division of Rheumatology, GRUA Investigation Group, Universidad de Antioquia, 650010 Medellín, Colombia. 2 IPS Artmedica, Medellín, Colombia. 3 Internal Medicine, Universidad Nacional de Colombia, Bogotá, Colombia.

Received: 4 December 2021   Accepted: 8 March 2022

Published online: 19 May 2022

References
1. Suichi T, Misawa S, Beppu M, Takahashi S, Sekiguchi Y, Shibuya K, et al. Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology. 2019;93(10):e975–83.
2. Brown R, Ginsberg L. POEMS syndrome: clinical update. J Neurol. 2019;266(1):268–77.
3. Nozza A. POEMS SYNDROME: an update. Mediterr J Hematol Infect Dis. 2019;15(398):121–7.
4. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.
5. Miest RYN, Comfere NL, Dispenzieri A, Lohse CM, el-Azhary RA. Cutaneous manifestations in patients with POEMS syndrome. Int J Dermatol. 2013;52:1349–56.
6. Rao RR, Yong WC, Wasko MC. Systemic light chain amyloidosis mimicking rheumatic disorders. Case Rep Med. 2016. https://doi.org/10.1155/2016/7649510.
7. Feldman L, Dhamne M, Li Y. Neurologic manifestations associated with cryoglobulinemia: a single center experience. J Neurol Sci. 2019;393:466–9.
8. Rpm, X. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.
9. Suichi T, Misawa S, Beppu M, Takahashi S, Sekiguchi Y, Shibuya K, et al. Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology. 2019;93(10):e975–83.
10. Brown R, Ginsberg L. POEMS syndrome: clinical update. J Neurol. 2019;266(1):268–77.
11. Nozza A. POEMS SYNDROME: an update. Mediterr J Hematol Infect Dis. 2019;15(398):121–7.
12. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.
13. Feldman L, Dhamne M, Li Y. Neurologic manifestations associated with cryoglobulinemia: a single center experience. J Neurol Sci. 2019;393:466–9.
8. Nakanishi T, Sobue I, Toyokura Y, Nishitani H, Kuroiwa Y, Satoyoshi E, Tsubaki T, Igata A, Ozaki Y. The Crow–Fukase syndrome: a study of 102 cases in Japan. Neurology. 1984;34(6):712–20.
9. Soubrier MJ, Dubost JJ, Sauzezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med. 1994;97(6):543–53.
10. Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, Park KS, Seo YI, Kim WU, Park SH, Cho CS. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol. 2003;30(7):1529–33.
11. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10):1685–99.
12. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013;15(3):21S.
13. Zhang B, Song X, Liang B, Hou Q, Pu S, Ying J, Gao C. The clinical study of POEMS syndrome in China. Neuro Endocrinol Lett. 2010;31(2):229–37.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.